You are using an older browser version. Please use a supported version for the best MSN experience.

GW PHARMACEUTICALS PLC

NASDAQ: GWPH
100.06
-0.12
-0.12%

Sector

Healthcare

Industry

Biotechnology & Medical Research

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company's lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD). The Company offers Sativex (nabiximols), which is indicated for the treatment of spasticity due to multiple sclerosis (MS). The Company is also focused on developing its pharmaceutical product pipelines, which includes Epidiolex for the treatment of Tuberous Sclerosis Complex and RETT Syndrome.

Key People

Geoffrey W. Guy

Executive Chairman of the Board

Justin Gover

Chief Executive Officer, Executive Director

Adam David George

Managing Director - U.K., Company Secretary

Christopher John Tovey

Chief Operating Officer

James Julian Noble

Non-Executive Independent Director

  • GW Pharmaceuticals PLC

  • Sovereign House, Vision Park, Chivers Way

  • CAMBRIDGE, CAMBRIDGESHIRE CB24 9BZ

  • GB.Map

  • Phone: +44 1223 266800

  • Fax: +44 1223 235667

  • https://www.gwpharm.com

Incorporated

2001

Employees

901

Insider Trades
  • Recent
  • All
  • Date

  • Name

  • Transaction

  • Shares

  • Price(s)

  • Value

    • 11/11/2019

    • GUY GEOFFREY W

    • Sold

    • 420,000

    • 113.23

    • 47,556,600.00

    • Date

    • Name

    • Transaction

    • Shares

    • Price(s)

    • Value

      • 11/11/2019

      • GUY GEOFFREY W

      • Sold

      • 420,000

      • 113.23

      • 47,556,600.00

      AdChoices
      AdChoices
      AdChoices
      image beaconimage beaconimage beacon